Leadiant Biosciences, S.p.A is a Rome-based global holding company, with subsidiaries in the US (Leadiant Biosciences, Inc.) and Europe (Leadiant Biosciences, Ltd). For region or country-specific product information, use the dropdown below.

We continue to honor our commitment to patients by advancing a diverse pipeline of new drugs and therapeutic candidates.

Leadiant Biosciences is a global, research-based pharmaceutical company focused on the discovery of molecules and therapies to help improve the lives of people around the world who suffer from specific diseases.

The study of rare diseases is an integral part of our research activity and heritage in rare diseases dating back to 1984, we have been among the first four Companies in the world to receive an Orphan Drug Designation in the United States. Since then, we have obtained seven more.

We continue to honor our commitment to patients by advancing a diverse pipeline of new drugs and therapeutic candidates. Our innovative research programs and development of novel product candidates are led by our scientists in partnership with a wide range of academic and biotechnology organizations.

Projects under investigation/development

The below chart reflects investigational drugs in various stages of clinical development for potential introduction into various markets. Safety and efficacy of the products has not yet been established for the proposed therapeutic areas.

Project Designation Proposed Therapeutic Area Stage of Development
roneparstat (heparanase inhibitor) Oncology Phase II
Heparanase inhibitor platform Oncology Pre-clinical
elapegademase (EZN-2279) Immunology Pre-clinical
elapegademase (EZN-2279) Immunology Phase III
STP-206 Neonatology Phase I/II
procarbazine hydrochloride Oncology Phase III
chenodiol Metabolic Phase III

Updated June 2017